Massachusetts Financial Services Co. MA Purchases 47,507 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Massachusetts Financial Services Co. MA lifted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 11.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 453,377 shares of the company's stock after buying an additional 47,507 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.70% of Kymera Therapeutics worth $21,458,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Comerica Bank increased its stake in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company's stock worth $134,000 after purchasing an additional 400 shares during the last quarter. Keudell Morrison Wealth Management increased its position in Kymera Therapeutics by 7.2% during the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company's stock worth $212,000 after buying an additional 480 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after buying an additional 504 shares during the period. American International Group Inc. lifted its position in shares of Kymera Therapeutics by 6.4% in the first quarter. American International Group Inc. now owns 20,095 shares of the company's stock valued at $808,000 after buying an additional 1,209 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $61,000.

Kymera Therapeutics Stock Down 2.2 %

Shares of KYMR stock traded down $1.04 during trading hours on Tuesday, reaching $45.98. The company's stock had a trading volume of 967,461 shares, compared to its average volume of 588,180. Kymera Therapeutics, Inc. has a fifty-two week low of $18.89 and a fifty-two week high of $53.27. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -19.65 and a beta of 2.21. The firm's 50 day simple moving average is $46.91 and its 200-day simple moving average is $42.04.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics's quarterly revenue was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.90) EPS. Sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the firm's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.82% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Guggenheim increased their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Wolfe Research raised shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 target price for the company in a report on Monday, August 26th. UBS Group lowered their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating on the stock in a report on Monday, November 4th. Oppenheimer boosted their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday, September 27th. Finally, Wells Fargo & Company lifted their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an "equal weight" rating in a report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $52.13.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.